Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003)

November 5, 2026: Immutep Limited (ASX: IMM, NASDAQ: IMMP) said it will present data from two Phase II trials of eftilagimod alfa (efti) in combination with pembrolizumab at upcoming 2026 conferences. At the CTOS 2026 Annual Meeting in Seoul (18–21 November 2026), the investigator-initiated EFTISARC-NEO Phase II trial (NCT06128863) will present disease-free survival data in resectable soft tissue sarcoma treated with neoadjuvant efti, pembrolizumab, and radiotherapy; the poster discussion is scheduled for November 19, 2026.

At the ESMO Immuno-Oncology & Advanced Therapies Congress 2026 in London (14–16 December 2026), final median overall survival results from TACTI-003 Part B, a Phase II trial (NCT04811027), will be presented in first-line recurrent or metastatic head and neck squamous cell carcinoma patients with PD-L1 CPS under 1 receiving efti plus pembrolizumab. That poster session is scheduled for December 14, 2026.

The release announces conference presentations only; no efficacy results were disclosed in the text. Immutep said the data will be posted on its website after presentation.